Chloroquine
Aralen (chloroquine) is a small molecule pharmaceutical. Chloroquine was first approved as Aralen hydrochloride on 1982-01-01. It is used to treat amebiasis, avian malaria, discoid lupus erythematosus, falciparum malaria, and malaria amongst others in the USA. It is known to target mas-related G-protein coupled receptor member X1 and prosaposin.
Download report
Favorite
COVID-19
Case Study: COVID-19
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chloroquine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARALEN HYDROCHLORIDE | Sanofi | N-006002 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Chloroquine phosphate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARALEN | Sanofi | N-006002 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Chloroquine phosphate
+
Primaquine phosphate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | Sanofi | N-014860 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
chloroquine phosphate | ANDA | 2023-05-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
amebiasis | EFO_0007144 | D000562 | A06 |
avian malaria | — | D008289 | — |
discoid lupus erythematosus | — | D008179 | L93.0 |
falciparum malaria | EFO_0007444 | D016778 | B50 |
malaria | EFO_0001068 | D008288 | B54 |
pemphigus | EFO_1000749 | D010392 | L10 |
rheumatoid arthritis | EFO_0000685 | D001172 | M06.9 |
systemic scleroderma | EFO_0000717 | D012595 | M34 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J0390 | Injection, chloroquine hydrochloride, up to 250 mg |
Clinical
Clinical Trials
156 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malaria | D008288 | EFO_0001068 | B54 | 10 | 5 | 15 | 7 | 12 | 47 |
Vivax malaria | D016780 | EFO_0007445 | B51 | — | 7 | 7 | 11 | 4 | 28 |
Falciparum malaria | D016778 | EFO_0007444 | B50 | 2 | 8 | 8 | 6 | 5 | 24 |
Covid-19 | D000086382 | U07.1 | 1 | 10 | 7 | 5 | 2 | 21 | |
Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 2 | 1 | 2 | 5 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 2 | 1 | — | 4 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 2 | 1 | 1 | 4 |
Asymptomatic diseases | D058070 | — | — | 1 | 1 | — | 2 | ||
Sars-cov-2 | D000086402 | — | — | 1 | 1 | — | 2 | ||
Glucosephosphate dehydrogenase deficiency | D005955 | EFO_0007287 | — | 1 | — | 1 | — | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | 2 | 1 | 1 | — | — | 4 | |
Hiv | D006678 | O98.7 | — | — | 1 | — | 2 | 3 | |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 1 | — | 1 | 3 |
Coronavirus | D017934 | — | — | 1 | — | 1 | 2 | ||
Sexually transmitted diseases | D012749 | A50-A64 | — | — | 1 | — | — | 1 | |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | 1 | — | — | 1 |
Chikungunya virus | D002646 | — | — | 1 | — | — | 1 | ||
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 2 | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | 1 | 2 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
Multiple myeloma | D009101 | C90.0 | — | 1 | — | — | — | 1 | |
Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | 1 | 1 | — | — | — | 1 | |
Cholangiocarcinoma | D018281 | C22.1 | 1 | 1 | — | — | — | 1 | |
Chondrosarcoma | D002813 | 1 | 1 | — | — | — | 1 | ||
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | — | 1 | 1 |
Parasitemia | D018512 | — | — | — | — | 1 | 1 | ||
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
Dyslipidemias | D050171 | HP_0003119 | — | — | — | — | 1 | 1 | |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | — | 1 | 1 |
Overweight | D050177 | E66.3 | — | — | — | — | 1 | 1 | |
Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
Birth weight | D001724 | EFO_0004344 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CHLOROQUINE |
INN | chloroquine |
Description | Chloroquine is an aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. It has a role as an antimalarial, an antirheumatic drug, a dermatologic drug, an autophagy inhibitor and an anticoronaviral agent. It is an aminoquinoline, a secondary amino compound, a tertiary amino compound and an organochlorine compound. It is a conjugate base of a chloroquine(2+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12 |
Target
Agency Approved
No data
Alternate
MRGPRX1
MRGPRX1
PSAP
PSAP
Organism
Homo sapiens
Gene name
MRGPRX1
Gene synonyms
MRGX1, SNSR3, SNSR4
NCBI Gene ID
Protein name
mas-related G-protein coupled receptor member X1
Protein synonyms
G protein-coupled receptor MRGX1, G protein-coupled receptor SNSR3, Mas-related G protein-coupled receptor G2, MAS-related GPR, member X1, Sensory neuron-specific G-protein coupled receptor 3/4
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 60,695 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,514 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more